TrialNature communications2025

Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial.

Brittany N Flores et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.